Table 1 Incidence of SARS-CoV-2 infection in persons with Cystic Fibrosis (pwCF), January 2020 to April 2023
References | Study design | Number of patients | Period(s) | Main findings |
|---|---|---|---|---|
Colombo C. et al. SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020. PLoS ONE 2021, 16, e0251527. [14] | Multicenter prospective study conducted in Italy | 6597 | February–July 2020 | pwCF had lower incidence of SARS-CoV-2 infection compared to the general population (2.4/1000 pwCF vs. 4.1/1000 inhabitants) |
Naehrlich L. et al. Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020 J. Cyst. Fibros. 2021, 20, 566–577 [15] | Observational study within the European Cystic Fibrosis Society Patient Registry | 130 PCR-confirmed cases | 01 February 2020 and 30 June 2020, with data follow-up until 07 January 2021 | The incidence of PCR-confirmed SARS-CoV-2 in pwCF (2.70 cases per 1000; 95% CI 2.25–3.20) was not statistically different to that of the general population (3.10/1000; 95% CI 3.10–3.11) Incidence was significantly higher in lung-transplanted pwCF (8.43/1000, 95% CI 5.35–12.62) versus non-lung transplanted pwCF (2.36/1000, 95% CI 1.94–2.86) |
Mondejar-Lopez P. et al. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey. Respir. Med. 2020,170, 106062 [16] | Retrospective observational study, based on the CF—confirmed COVID-19 Registry, Spain | 2498 | 8 March–16 May 2020 | Lower accumulated incidence in CF patients (32/10,000) than in the general population (49/10,000) |
Padoan R. et al. First and second wave of SARS-CoV2 in Italian Cystic Fibrosis patients: Data from Italian Cystic Fibrosis Registry. Journal of Cystic Fibrosis 20 (2021) 372–373 [17] | Survey based-study involving the CF Centers located in Italy | 5501 | February-November 2020 | First wave (February to August 2020) 22 CF patients were positive to SARS-CoV-2 virus i.e. 0.40% (0.23–0.57 CI95%) Second wave (September–November 2020) 65 CF patients i.e. 1.18% (0.90–1.47 CI95%) |
Corvol H. et al. First Wave of COVID-19 in French Patients with Cystic Fibrosis J Clin Med. 2020 Nov 10;9(11):3624. [18] | Prospective observational study conducted in France | 7500 | 1 March–30 June 2020 | Lower incidence and overall risk reduction in pwCF with respect to the general population |
Berardis S. et al. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. J. Cyst. Fibros. 2020, 19, 872–874. [19] | Prospective single center study conducted in Belgium | 149 | April 16, 2020–May 19, 2020 | Lower seroprevalence in pwCF (2.7%) than in the Belgian population (4.3%) in the same period |